Cargando…

Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro

BACKGROUND: The non-thrombotic effects of thrombin in cardiovascular tissues, as mediated via the protease activated receptors (PARs), and particularly PAR-1, have been the focus of much recent research. The aims of this study were to evaluate the effects of thrombin, a specific PAR-1 activating pep...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Loughlin, Aonghus J, O'Sullivan, Crochan J, Ravikumar, Nandini, Friel, Anne M, Elliott, John T, Morrison, John J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC554978/
https://www.ncbi.nlm.nih.gov/pubmed/15730558
http://dx.doi.org/10.1186/1477-7827-3-8
_version_ 1782122525000466432
author O'Loughlin, Aonghus J
O'Sullivan, Crochan J
Ravikumar, Nandini
Friel, Anne M
Elliott, John T
Morrison, John J
author_facet O'Loughlin, Aonghus J
O'Sullivan, Crochan J
Ravikumar, Nandini
Friel, Anne M
Elliott, John T
Morrison, John J
author_sort O'Loughlin, Aonghus J
collection PubMed
description BACKGROUND: The non-thrombotic effects of thrombin in cardiovascular tissues, as mediated via the protease activated receptors (PARs), and particularly PAR-1, have been the focus of much recent research. The aims of this study were to evaluate the effects of thrombin, a specific PAR-1 activating peptide (PAR1-AP), and a PAR-1 antagonist on human umbilical artery tone in vitro. METHODS: Human umbilical artery samples were obtained from 17 women at term. Arterial rings were suspended under physiologic conditions for isometric recording. The in vitro effects of thrombin (0.5 units/mL to 3 units/mL), PAR1-AP TFLLR-NH2 [10(-9) to 10(-6) M], and PAR-1 antagonist (N-trans cinnamoyl- p-fluoroPhe-p-guanidinoPhe-Leu-Arg-Orn-NH2) [10(-9) M to 10(-5) M] on umbilical artery tone were measured. RESULTS: Both thrombin and TFLLR-NH2 exerted a potent cumulative vasodilatory effect on human umbilical artery resistance (P < 0.001). The mean net maximal inhibition (MMI) for thrombin was 53.05% (n = 6; SEM = 1.43) at tissue bath concentration of 3 units/mL. The MMI with TFLLR-NH2 was 61.50 % (n = 6; SEM = 1.43) at bath concentration of 10(-6) M. In comparison to vehicle control, the PAR-1 antagonist did not show a significant relaxant or contractile effect (P > 0.05). CONCLUSION: These findings highlight a potential role for thrombin and PAR-1 receptors in vascular regulation of feto-placental blood flow in normal pregnancy, and in association with the vascular lesions associated with IUGR and pre-eclampsia.
format Text
id pubmed-554978
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5549782005-03-20 Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro O'Loughlin, Aonghus J O'Sullivan, Crochan J Ravikumar, Nandini Friel, Anne M Elliott, John T Morrison, John J Reprod Biol Endocrinol Research BACKGROUND: The non-thrombotic effects of thrombin in cardiovascular tissues, as mediated via the protease activated receptors (PARs), and particularly PAR-1, have been the focus of much recent research. The aims of this study were to evaluate the effects of thrombin, a specific PAR-1 activating peptide (PAR1-AP), and a PAR-1 antagonist on human umbilical artery tone in vitro. METHODS: Human umbilical artery samples were obtained from 17 women at term. Arterial rings were suspended under physiologic conditions for isometric recording. The in vitro effects of thrombin (0.5 units/mL to 3 units/mL), PAR1-AP TFLLR-NH2 [10(-9) to 10(-6) M], and PAR-1 antagonist (N-trans cinnamoyl- p-fluoroPhe-p-guanidinoPhe-Leu-Arg-Orn-NH2) [10(-9) M to 10(-5) M] on umbilical artery tone were measured. RESULTS: Both thrombin and TFLLR-NH2 exerted a potent cumulative vasodilatory effect on human umbilical artery resistance (P < 0.001). The mean net maximal inhibition (MMI) for thrombin was 53.05% (n = 6; SEM = 1.43) at tissue bath concentration of 3 units/mL. The MMI with TFLLR-NH2 was 61.50 % (n = 6; SEM = 1.43) at bath concentration of 10(-6) M. In comparison to vehicle control, the PAR-1 antagonist did not show a significant relaxant or contractile effect (P > 0.05). CONCLUSION: These findings highlight a potential role for thrombin and PAR-1 receptors in vascular regulation of feto-placental blood flow in normal pregnancy, and in association with the vascular lesions associated with IUGR and pre-eclampsia. BioMed Central 2005-02-24 /pmc/articles/PMC554978/ /pubmed/15730558 http://dx.doi.org/10.1186/1477-7827-3-8 Text en Copyright © 2005 O'Loughlin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
O'Loughlin, Aonghus J
O'Sullivan, Crochan J
Ravikumar, Nandini
Friel, Anne M
Elliott, John T
Morrison, John J
Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title_full Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title_fullStr Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title_full_unstemmed Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title_short Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro
title_sort effects of thrombin, par-1 activating peptide and a par-1 antagonist on umbilical artery resistance in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC554978/
https://www.ncbi.nlm.nih.gov/pubmed/15730558
http://dx.doi.org/10.1186/1477-7827-3-8
work_keys_str_mv AT oloughlinaonghusj effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro
AT osullivancrochanj effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro
AT ravikumarnandini effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro
AT frielannem effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro
AT elliottjohnt effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro
AT morrisonjohnj effectsofthrombinpar1activatingpeptideandapar1antagonistonumbilicalarteryresistanceinvitro